Meeting
2020 ASCO Virtual Scientific Program
Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2–advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW.
Authors
Manish A. Shah
Weill Cornell Medical College, New York, NY
Manish A. Shah , Jaffer A. Ajani , Salah-Eddin Al-Batran , Yung-Jue Bang , Daniel Catenacci , Peter C. Enzinger , David H. Ilson , Sunnie Kim , Florian Lordick , Kohei Shitara , Eric Van Cutsem , Ahsan Arozullah , Jung Wook Park , Rui-hua Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03653507
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS4648)
DOI
10.1200/JCO.2020.38.15_suppl.TPS4648
Abstract #
TPS4648
Poster Bd #
256
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2– advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.
First Author: Manish A. Shah
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3.
First Author: Samuel J Klempner
Poster
2021 ASCO Annual Meeting
Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.
First Author: Weijian Guo
Poster
2018 Gastrointestinal Cancers Symposium
Health-related quality-of-life (HRQoL) results from the FAST study: A phase II trial of epirubicin, oxaliplatin, and capecitabine with or without IMAB362 in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma.
First Author: Robert Morlock